Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07546591 · ClinicalTrials.gov registry record · NA
A Pilot Study to Evaluate the Ability of Lactoferrin to Modulate Iron Homeostasis and Exercise Performance in Exercising Females
A NA study, sponsored by Lindenwood University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT07546591: Recruiting NA study, sponsored by Lindenwood University.
NCT07546591 is a NA study that is actively recruiting participants, run by Lindenwood University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07546591, a NA study, is actively recruiting participants, sponsored by Lindenwood University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This randomized, double-blind, active-controlled trial will evaluate the effects of human lactoferrin supplementation combined with low-dose iron on iron status, aerobic performance, and lactate metabolism in exercising women with low ferritin. Approximately 30 healthy, menstruating women aged 18-45 years with serum ferritin \<35 µg/L will be enrolled in an 8-week intervention. Participants will be stratified by baseline ferritin status and randomized to receive 100 mg lactoferrin + 5 mg iron, 300 mg lactoferrin + 5 mg iron, or placebo + 5 mg iron daily. Primary outcomes include changes in ferritin and hematological parameters. Secondary outcomes include VO₂peak, time to exhaustion, and blood lactate responses during standardized treadmill testing. This study will determine whether lactoferrin enhances iron homeostasis and improves physiological and performance outcomes in exercising women with low iron stores.
Primary Outcome
Serum ferritin concentration will be assessed via venous blood samples to evaluate changes in iron storage over the intervention period.
Interventions
- DIETARY_SUPPLEMENT Lactoferrin 100 mg
- DIETARY_SUPPLEMENT Lactoferrin 300 mg
- DIETARY_SUPPLEMENT Iron Supplementation (5 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2027-04-30 |
| Phase | NA |
What NCT07546591 shows while recruiting
NCT07546591 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Lactoferrin 100 mg is the first listed.
NCT07546591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07546591 about?
NCT07546591 is a clinical study titled "A Pilot Study to Evaluate the Ability of Lactoferrin to Modulate Iron Homeostasis and Exercise Performance in Exercising Females". This randomized, double-blind, active-controlled trial will evaluate the effects of human lactoferrin supplementation combined with low-dose iron on iron status, aerobic performance, and lactate metabolism in exercising women with low ferritin. Approximately 30 healthy, menstruating women aged 18-45...
What is the current status of trial NCT07546591?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-04-30. Estimated completion is 2027-04-30.
What interventions are being tested in trial NCT07546591?
The interventions under investigation include: Lactoferrin 100 mg (DIETARY_SUPPLEMENT), Lactoferrin 300 mg (DIETARY_SUPPLEMENT), Iron Supplementation (5 mg) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07546591?
This trial is sponsored by Lindenwood University, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07546591's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI